Conditions in the coagulant and anticoagulant activity of blood in patients with coronary heart disease with concomitant diabetes mellitus type 2, depending on the his compensation

Authors

  • Yuliya Zolotukhina Bogomolets National Medical University Tarasa Shevchenko blvd., 13, Kyiv, Ukraine, 01601 Kyiv Clinical Hospital on the railway transport No. 2 of the branch "Health Center" of the Public Joint Stock Company "Ukrainian Railway" Povitroflotskyi ave., 9, Kyiv, Ukraine, 03049, Ukraine https://orcid.org/0000-0002-0451-0601

DOI:

https://doi.org/10.15587/2519-4798.2019.155751

Keywords:

thrombosis, hemostasis, ischemic heart disease, the coagulant and anticoagulant system, type 2 diabetes mellitus

Abstract

The aim: to evaluate and analyze the parameters of coagulant and anticoagulant activity in the blood in different groups of patients with coronary heart disease without and with associated Diabetes Mellitus (DM) type 2 depending on its compensation.

Materials: during the study of the coagulant and anticoagulant activity in the blood system, 52 patients were hospitalized in the cardiology and endocrinology department of the Kyiv Clinical Hospital on Railway Transport No. 2 of the Health Protection Center branch of the Ukrainian Railways Public Joint-Stock Company (clinical base of the Department of Internal Medicine Propedeutics No. 1 of the National OO Bogomolets Medical University) with clinical signs of coronary artery disease. Patients were divided into three groups: 27 patients with IHD and with type 2 diabetes in the subcompensation stage, 14th - compensation stage and 11th - decompensation stage.

Results: after analyzing the data, at all stages of compensation there was a decrease in all indicators of coagulation hemostasis: APTT - by 6,94 % (compensation stage (I)) (p<0,05) and 13,7 % (decompensation stage (III)) (p<0,01), PTT - by 9,14 % (І) (р<0,01), by 6,43 % (the stage of subcompensation (II) (p<0,05), by 10,3 % (ІІІ ) (p<0,001), TT - by 15,54 % (I) (p<0,001), by 19,2 % (II) (p<0,001), by 20,9 % (III) (p<0,001) and also an increase in the level of fibrinogen by 32,16 % (I) (p<0,001), by 36,04 % (II) (p<0,001), by 48,06 % (III) (p<0,001), which indicates about accelerating the processes of coagulation at once in three links: reduction of the periods of generation of active trombin by internal and external mechanisms with simultaneous activation of fibrogenesis (factor IIA and fibrin). The anticoagulant potential was reduced: AT III by 16,5 % (I) (p<0,001), by 22,7 % (II) (p<0.001) , by 23,6 % (ІІІ) (p<0,001), and PS - by 18,63 % (I and ІІ) (p<0,001). It should be noted that when comparing the groups between themselves, a significant decrease in AT III between the stages of subcompensation and decompensation on 8,5 % (p<0,05).

Conclusion: it should be noted that in patients with comorbid IHD with type 2 diabetes, hypercoagulable shifts in the hemostasis system occurred against the background of inhibition of the own anticoagulant blood potential. Changes in the coagulation potential in the combination of type 2 DM were marked by accelerating the processes of coagulation at once in all three stages of coagulation (prothrombinase, thrombin and fibrin formation)

Author Biography

Yuliya Zolotukhina, Bogomolets National Medical University Tarasa Shevchenko blvd., 13, Kyiv, Ukraine, 01601 Kyiv Clinical Hospital on the railway transport No. 2 of the branch "Health Center" of the Public Joint Stock Company "Ukrainian Railway" Povitroflotskyi ave., 9, Kyiv, Ukraine, 03049

Postgraduate student

Department of Propaedeutics of Internal Medicine No. 1

References

  1. Kuzin, A. I., Cherednikova, M. A., Vasiliev, A. A., Kamerer, O. V. (2014). Arterial hypertension and diabetes mellitus type 2 in patients with metabolic syndrome: features of the effect on the lipid spectrum. Arterial hypertension, 9 (2), 67–70.
  2. Kaminsky, A. V., Samoilov, A. A. (2002). Insulin resistance syndrome in patients with type 2 diabetes mellitus and its drug correction. Clinical Endocrinology and Endocrine Surgery.
  3. Watkins, P. J. (2003). ABC of diabetes. London: BMJ Pub. Group, 101.
  4. Turner, R. C., Millns, H., Neil, H. A. W., Stratton, I. M., Manley, S. E., Matthews, D. R., Holman, R. R. (1998). Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ, 316 (7134), 823–828. doi: http://doi.org/10.1136/bmj.316.7134.823
  5. Barter, P., McPherson, Y. R., Song, K., Kesäniemi, Y. A., Mahley, R., Waeber, G. et. al. (2007). Serum Insulin and Inflammatory Markers in Overweight Individuals with and without Dyslipidemia. The Journal of Clinical Endocrinology & Metabolism, 92 (6), 2041–2045. doi: http://doi.org/10.1210/jc.2006-2219
  6. Chiha, M., Njeim, M., Chedrawy, E. G. (2012). Diabetes and Coronary Heart Disease: A Risk Factor for the Global Epidemic. International Journal of Hypertension, 2012, 1–7. doi: http://doi.org/10.1155/2012/697240
  7. Kishore, P., Kim, S. H., Crandall, J. P. (2012). Glycemic Control and Cardiovascular Disease: What’s a Doctor to Do? Current Diabetes Reports, 12 (3), 255–264. doi: http://doi.org/10.1007/s11892-012-0268-5
  8. Kaydashev, I. P. (2011). Nf-kb-signaling as the basis for the development of systemic inflammation, insulin resistance, lipotoxicity, type 2 diabetes mellitus and atherosclerosis. International Endocrinological Journal, 3. Available at: http://www.mif-ua.com/archive/article/17762
  9. Martishin, O. O. (2017). Diabetes and cardiovascular diseases are associated with magnesium levels in the blood. Ukrainian Medical Watch Room. Available at: https://www.umj.com.ua/article/114861/saharnyj-diabet-i-serdechno-sosudistye-zabolevaniya-svyazany-s-urovnem-magniya-v-krovi
  10. Severin, A. S., Shestakova, M. V. (2004). Disruption of the hemostatic system in patients with diabetes mellitus. Diabetes, 1, 62–67.
  11. Schneider, D. J., Nordt, T. K., Sobel, B. E. (1993). Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes, 42 (1), 1–7. doi: http://doi.org/10.2337/diabetes.42.1.1
  12. Erem, C., Hacıhasanoğlu, A., Çelik, Ş., Ovalı, E., Ersöz, H. Ö., Ukinç, K. et. al. (2004). Coagulation and Fibrinolysis Parameters in Type 2 Diabetic Patients with and without Diabetic Vascular Complications. Medical Principles and Practice, 14 (1), 22–30. doi: http://doi.org/10.1159/000081919
  13. Wilson, P. W. F., Meigs, J. B., Sullivan, L. (2007). Prediction of Incident Diabetes Mellitus in Middle-aged Adults: The Framingham Offspring Study. Archives of Internal Medicine, 167 (10), 1068. doi: http://doi.org/10.1001/archinte.167.10.1068
  14. Stamler, J., Neaton, J. D., Cohen, J. D., Cutler, J., Eberly, L. et. al. (2012). Multiple Risk Factor Intervention Trial Revisited: A New Perspective Based on Nonfatal and Fatal Composite Endpoints, Coronary and Cardiovascular, During the Trial. Journal of the American Heart Association, 1 (5). doi: http://doi.org/10.1161/jaha.112.003640
  15. King, P., Peacock, I., Donnelly, R. (2001). The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes. British Journal of Clinical Pharmacology, 48 (5), 643–648. doi: http://doi.org/10.1046/j.1365-2125.1999.00092.x
  16. Meigs, J. B., Mittleman, M. A., Nathan, D. M., Tofler, G. H., Singer, D. E., Murphy-Sheehy, P. M. et. al. (2000). Hyperinsulinemia, Hyperglycemia, and Impaired Hemostasis. JAMA, 283 (2), 221–228. doi: http://doi.org/10.1001/jama.283.2.221
  17. Barkagan, Z. S., Momot, A. P. (2008). Diagnostika i kontroliruemaya terapiya narusheniy gemostaza. Moscow: N'yudiamed, 289.
  18. Barkagan, Z. S., Momot, A. P. (2001). Diagnostika i kontroliruemaya terapiya narusheniy gemostaza. Moscow: N'yudiamed, 296.
  19. Kozlov, A. A., Natrus, L. V., Chernovol, P. A., Melkumyanidr, A. L. et. al. (2011). Laboratory diagnosis of hemostasis. Moscow: Litterra, 136.
  20. Asakawa, H., Tokunaga, K., Kawakami, F. (2000). Elevation of fibrinogen and thrombin–antithrombin III complex levels of type 2 diabetes mellitus patients with retinopathy and nephropathy. Journal of Diabetes and Its Complications, 14 (3), 121–126. doi: http://doi.org/10.1016/s1056-8727(00)00075-1
  21. Carr, M. E. (2001). Diabetes mellitus: a hypercoagulable state. Journal of Diabetes and Its Complications, 15 (1), 44–54. doi: http://doi.org/10.1016/s1056-8727(00)00132-x
  22. Gabazza, E. C., Takeya, H., Deguchi, H., Sumida, Y., Taguchi, O., Murata, K. et. al. (1996). Protein C activation in NIDDM patients. Diabetologia, 39 (12), 1455–1461. doi: http://doi.org/10.1007/s001250050598
  23. Kvasnicka, J., Skrha, J., Perusicová, J., Kvasnicka, T., Marková, M., Umlaufová, A. et. al. (1998). Haemostasis, cytoadhesive molecules (sE-selectin and sICAM-1) and inflammatory markers in non-insulin dependent diabetes mellitus (NIDDM). Sb Lek, 99 (2), 97–101. Available at: https://www.ncbi.nlm.nih.gov/pubmed/10536488
  24. Junbin, H., Wenning, W., Guizhi, D., Li, Y., Zhongpin, L. (1998). Variations and clinical significance of coagulation and fibrinolysis parameters in patients with diabetes mellitus. Journal of Tongji Medical University, 18 (4), 233–235. doi: http://doi.org/10.1007/bf02886480
  25. Ceriello, A. (1993). Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia, 36 (11), 1119–1125. doi: http://doi.org/10.1007/bf00401055
  26. Dresslerova, I., Vojacek, J. (2010). Diabetes mellitus and ischemic heart disease. Vnitr Lek, 56 (4), 301–306. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20465100

Downloads

Published

2019-02-04

How to Cite

Zolotukhina, Y. (2019). Conditions in the coagulant and anticoagulant activity of blood in patients with coronary heart disease with concomitant diabetes mellitus type 2, depending on the his compensation. ScienceRise: Medical Science, (1 (28), 14–19. https://doi.org/10.15587/2519-4798.2019.155751

Issue

No. 1 (28) (2019)

Section

Medical Science

License

Copyright (c) 2019 Yuliya Zolotukhina

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.